Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today reported fiscal ...

Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful ...

A fireside chat with a Tamika D. Mallory will go down at sunset to inspire attendees. Powered by Novartis, Grow with Google, Chase for Business, and Barbados Tourism Marketing, the Pow(H)er Experience ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...

In a significant stride within the pharmaceutical industry, Midtown's own Schrödinger has clinched a deal with healthcare ...

Palla was also impressed by the firm’s client roster. She noted that White & Case has worked with significant life sciences ...